Phalanx Biotech
Phalanx Biotech, operating as HuaLien Biotech in Taiwan, was founded in 2002 as a spin-off from Taiwan's Industrial Technology Research Institute (ITRI).
Profile
Develops genetic testing kits and analysis services for hospitals and research labs.
Phalanx Biotech, operating as HuaLien Biotech in Taiwan, was founded in 2002 as a spin-off from Taiwan's Industrial Technology Research Institute (ITRI). The company specializes in genetic testing platforms, with a focus on microarray chips, next-generation sequencing, and bioinformatics. Headquartered in Hsinchu Biomedical Science Park, it has positioned itself as Asia's sole high-density gene chip manufacturer.
Phalanx serves clinical diagnostics and research markets with products spanning prenatal testing, reproductive medicine, cancer risk assessment, and chronic disease screening. The company has expanded to 17 countries, though Taiwan remains its core market. While private and not disclosing financials, Phalanx has sustained operations for over two decades in the competitive genetic diagnostics space.
Recent activity includes launching a third-generation amniotic fluid chromosome chip (Cyto OneArray V3) and expanding non-invasive prenatal testing (NIPT) offerings. The company faces pressure from multinational diagnostics firms but maintains niche advantages in Asian population-specific genetic markers.
Who buys this
- Obstetrics and gynecology clinics offering prenatal diagnostics
- Fertility centers providing IVF and embryo screening
- Oncology departments requiring hereditary cancer risk assessments
- Academic and pharmaceutical research institutions
- Public health programs implementing newborn screening
Strengths and what to watch
Strengths
- Proprietary microarray chip manufacturing capability reduces reliance on imported diagnostics
- Established reimbursement pathways for prenatal tests in Taiwan's national health system
- Localized genetic databases for East Asian populations unlike global competitors
Watch for
- Dependence on Taiwan's regulated healthcare market for majority revenue
- Intellectual property disputes with multinationals over chip design patents
- Slow adoption of newer NIPT technology compared to legacy microarray products
Recent moves
Key Information
- Founded
- 2002
- Headquarters
- Hsinchu Biomedical Science Park, Taiwan
Frequently Asked Questions
What does Phalanx Biotech specialize in?
Phalanx Biotech develops genetic testing kits and analysis services, focusing on microarray chips, next-generation sequencing, and bioinformatics. The Taiwan-based company serves hospitals and labs with products for prenatal testing, cancer risk assessment, and chronic disease screening. It's Asia's sole high-density gene chip manufacturer, operating since 2002.
What types of genetic tests does Phalanx Biotech offer?
Phalanx provides tests for prenatal diagnostics (including NIPT), reproductive medicine, hereditary cancer risk, and chronic diseases. Their Cyto OneArray V3 amniotic fluid chromosome chip is used for advanced prenatal screening. The company tailors tests for East Asian populations using localized genetic databases.
Who uses Phalanx Biotech's services?
Major customers include OB-GYN clinics, fertility centers, oncology departments, research institutions, and public health programs. In Taiwan, their tests are reimbursed for prenatal diagnostics. The company serves 17 countries but remains strongest in domestic markets requiring Asian-specific genetic markers.
How does Phalanx Biotech compare to global genetic testing companies?
Phalanx holds niche advantages in Asian population genetics and owns proprietary microarray chip manufacturing. While facing competition from multinationals, it maintains reimbursement pathways in Taiwan's health system. The company focuses on clinical diagnostics rather than direct-to-consumer genetic testing.
What's new with Phalanx Biotech's prenatal testing?
Recently launched Cyto OneArray V3 improves amniotic fluid chromosome analysis. The company also expanded non-invasive prenatal testing (NIPT) offerings. Their tests are included in Taiwan's IVF subsidy programs, as updated in February 2026 guidance for healthcare providers.
Where is Phalanx Biotech headquartered?
The company operates from Hsinchu Biomedical Science Park in Taiwan, where it originated as a 2002 spin-off from Taiwan's Industrial Technology Research Institute (ITRI). This location provides access to semiconductor manufacturing expertise crucial for microarray chip production.
Sources
- www.phalanxbiotech.com — Company history, product portfolio, and operational scope
- www.phalanx.com.tw — 2024 operational update on holiday schedule
- www.phalanx.com.tw — 2026 content update on IVF subsidies
- www.phalanx.com.tw — Product details for Cyto OneArray V3